Amgen Rises by 2% as XBI’s Large-Cap Stocks Rally
Amgen closed at $157.60 and was trading above its 50- and 100-day moving averages. The stock also witnessed a rise in trading volumes.
Alexion Continues to Rise on FDA’s Approval of Kanuma
Alexion Pharmaceuticals (ALXN) gained 2.5% on December 10, 2015. The stock went up after the FDA (Food and Drug Administration) approved its drug, Kanuma.
Alkermes in the Third Quarter: A Performance Overview
Alkermes (ALKS) reported its third-quarter results on October 23. It generated net revenues of $248.7 million, a 14% YoY growth.
What Does Nektar Therapeutics’ Valuation Trend Indicate?
Under its immunology program, Nektar Therapeutics (NKTR) is developing NKTR-358 in collaboration with Eli Lilly and Company (LLY).
Exploring Alkermes’ Financial Performance in Fiscal 2017
Alkermes (ALKS) generated total revenues of $903.0 million in fiscal 2017 compared with $745.6 million in fiscal 2016.
An Insight into Alkermes’ R&D Pipeline
Alkermes’ ALKS3831 is an investigational oral medicine is targeted for the treatment of schizophrenia.
A Look at Alkermes’ Diabetes Product Portfolio
According to Alkermes, ~26.0 million people in the US and 382.0 million people globally are affected by diabetes.
A Deeper Look at Alkermes’ Key Marketed Products
Alkermes’ (ALKS) Aristada is an intramuscular injectable suspension for the treatment of schizophrenia.
Analysts’ Ratings for Alkermes and Its Peers in February 2018
Of the 12 analysts covering Alkermes (ALKS) in February, five analysts gave ALKS a “buy” rating. Seven analysts gave it a “hold” rating.
Analyst Ratings for Vanda Pharmaceuticals and Peers in February
Of the six analysts covering Vanda Pharmaceuticals in February 2018, two of them have given the stock a “strong buy” rating.
What’s the Sector Composition of the FNGAX?
The Franklin International Growth Fund invests “in the equity securities of mid- and large-capitalization companies outside the U.S. with long-term growth potential.”
The Franklin International Growth Fund’s Portfolio Moves in YTD 2016
In the past 12 months until May 2016, Franklin International Growth Fund (FNGAX) has witnessed increased exposure to discretionary and healthcare stocks.
XBI News as of March 16: Mid-Caps Under Pressure
Given selling pressures, XBI’s 18 mid-cap stocks went down marginally on average, losing 0.4% on March 16. Eight stocks advanced while ten stocks declined.
What You Should Know about the Franklin International Growth Fund
The Franklin International Growth Fund – Class A (FNGAX) was incepted in June 2008 and has an expense ratio of 1.4%.
How Has the Fidelity Growth Company Fund Performed in 2016?
The Fidelity Growth Company Fund (FDGRX) was among the top five largest funds in this peer group, managing assets worth $36.0 billion as of January 2016.
Alkermes’s Aristada and Its FDA Approval for Schizophrenia
Aristada was approved by the FDA and is projected to account for 10% to 30% of the LAI atypical antipsychotic market for schizophrenia patients in the US.
Top Ten of XBI Outperform by Market Cap
The average return of the top ten IBB stocks was -4.73%, while the average return of top ten XBI stocks was -3.89% for the week ended September 4, 2015.
What Led Large-Cap Stocks to Outperform Mid and Small Caps?
Within the iShares Nasdaq Biotechnology ETF (IBB), for the week ending July 31, 2015, the top ten large-cap stocks had a weight of 56.59% of IBB’s portfolio.